Parathyroidectomy prior to kidney transplant decreases graft failure
Callender GG, Malinowski J, Javid M, Zhang Y, Huang H, Quinn CE, Carling T, Tomlin R, Smith JD, Kulkarni S. Parathyroidectomy prior to kidney transplant decreases graft failure. Surgery 2016, 161: 44-50. PMID: 27863776, DOI: 10.1016/j.surg.2016.10.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesConfidence IntervalsDatabases, FactualFemaleGraft RejectionGraft SurvivalHumansHyperparathyroidismKidney Failure, ChronicKidney TransplantationMaleMiddle AgedOdds RatioParathyroid HormoneParathyroidectomyPreoperative CareRetrospective StudiesRisk AssessmentTreatment OutcomeConceptsYear post-kidney transplantationPost-kidney transplantationDelayed graft functionGraft failureKidney transplantationGraft functionParathyroid hormoneUremic hyperparathyroidismKidney diseaseFirst year post-kidney transplantationSerum parathyroid hormone levelsCurrent Kidney DiseaseGlobal Outcomes (KDIGO) guidelinesParathyroid hormone levelsSerum parathyroid hormoneAdult patientsKidney transplantOutcomes guidelinesRetrospective reviewSingle institutionCurrent guidelinesHormone levelsSurvival 1ParathyroidectomyTransplantationEculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
Kulkarni S, Kirkiles‐Smith N, Deng YH, Formica RN, Moeckel G, Broecker V, Bow L, Tomlin R, Pober JS. Eculizumab Therapy for Chronic Antibody‐Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. American Journal Of Transplantation 2016, 17: 682-691. PMID: 27501352, DOI: 10.1111/ajt.14001.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntibodies, Monoclonal, HumanizedChronic DiseaseComplement C5Complement Inactivating AgentsEarly Intervention, EducationalFemaleFollow-Up StudiesGlomerular Filtration RateGraft RejectionGraft SurvivalHumansIsoantibodiesKidney Failure, ChronicKidney Function TestsKidney TransplantationLiving DonorsMaleMiddle AgedPilot ProjectsPrognosisRisk FactorsTissue DonorsTransplant RecipientsYoung AdultConceptsDe novo donor-specific antibodiesComplement inhibitionTreatment groupsNovo donor-specific antibodiesAntibody-Mediated InjuryC1q-positive patientsDonor-specific antibodiesKidney transplant recipientsPrimary end pointEndothelial cell injuryMo of observationEculizumab therapyEculizumab treatmentHumoral injuryTransplant recipientsKidney transplantRenal functionKidney functionChronic settingEGFR trajectoriesTreatment periodCell injuryPatientsEnd pointPercentage change